SEL103

SEL103 is a small molecule drug candidate developed for the symptomatic treatment of **Alzheimer's disease**. It originated from research at Polish universities and is being advanced through a collaboration between **Selvita**, responsible for discovery and early preclinical development, and **Orion Pharma**, which takes over further development and holds global commercialization rights after lead compound selection. The program achieved key research milestones, including the identification of lead molecules, but no public information is available on its mechanism of action, preclinical data, or current development status beyond early discovery/preclinical stages as of the latest reports.[5][7][8][9][11]